These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 35093083)

  • 1. Exploring the influencing factors of the pathologic complete response in estrogen receptor-positive, HER2-negative breast cancer after neoadjuvant chemotherapy: a retrospective study.
    Tang L; Shu X; Tu G
    World J Surg Oncol; 2022 Jan; 20(1):27. PubMed ID: 35093083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy evaluation of neoadjuvant chemotherapy in patients with HER2-low expression breast cancer: A real-world retrospective study.
    Tang L; Li Z; Jiang L; Shu X; Xu Y; Liu S
    Front Oncol; 2022; 12():999716. PubMed ID: 36605428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
    Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
    World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Nomogram to Predict the Pathologic Complete Response of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Based on Simple Laboratory Indicators.
    Zhang F; Huang M; Zhou H; Chen K; Jin J; Wu Y; Ying L; Ding X; Su D; Zou D
    Ann Surg Oncol; 2019 Nov; 26(12):3912-3919. PubMed ID: 31359285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individualized model for predicting pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: A multicenter study.
    Qian B; Yang J; Zhou J; Hu L; Zhang S; Ren M; Qu X
    Front Endocrinol (Lausanne); 2022; 13():955250. PubMed ID: 36060977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and Validation of a Nomogram for Individually Predicting Pathologic Complete Remission After Preoperative Chemotherapy in Chinese Breast Cancer: A Population-Based Study.
    Hou N; Xiao J; Wang Z; Wu Y; Hou G; Guo L; Zhang J; Ling R
    Clin Breast Cancer; 2020 Dec; 20(6):e682-e694. PubMed ID: 32713825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer.
    Yang ZJ; Xin F; Chen ZJ; Yu Y; Wang X; Cao XC
    BMC Cancer; 2024 Jan; 24(1):134. PubMed ID: 38273267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognosis and influencing factors of ER-positive, HER2-low breast cancer patients with residual disease after neoadjuvant chemotherapy: a retrospective study.
    Tang L; Jiang L; Shu X; Jin Y; Yu H; Liu S
    Sci Rep; 2024 May; 14(1):11761. PubMed ID: 38783028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy.
    Fujii T; Kogawa T; Wu J; Sahin AA; Liu DD; Chavez-MacGregor M; Giordano SH; Raghavendra A; Murthy RK; Tripathy D; Shen Y; Yamal JM; Ueno NT
    Br J Cancer; 2017 Feb; 116(4):509-514. PubMed ID: 28081544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Develop and Validate a Nomogram Combining Contrast-Enhanced Spectral Mammography Deep Learning with Clinical-Pathological Features to Predict Neoadjuvant Chemotherapy Response in Patients with ER-Positive/HER2-Negative Breast Cancer.
    Xing D; Lv Y; Sun B; Chu T; Bao Q; Zhang H
    Acad Radiol; 2024 Sep; 31(9):3524-3534. PubMed ID: 38641451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two nomograms to predict pathologic complete responses to neoadjuvant chemotherapy for breast cancer: evidence that HER2-positive tumors need specific predictors.
    Frati A; Chereau E; Coutant C; Bezu C; Antoine M; Chopier J; Daraï E; Uzan S; Gligorov J; Rouzier R
    Breast Cancer Res Treat; 2012 Apr; 132(2):601-7. PubMed ID: 22160638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer.
    Rouzier R; Pusztai L; Garbay JR; Delaloge S; Hunt KK; Hortobagyi GN; Berry D; Kuerer HM
    Cancer; 2006 Oct; 107(7):1459-66. PubMed ID: 16948128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
    Soliman H; Wagner S; Flake DD; Robson M; Schwartzberg L; Sharma P; Magliocco A; Kronenwett R; Lancaster JM; Lanchbury JS; Gutin A; Gradishar W
    Ann Surg Oncol; 2020 Mar; 27(3):765-771. PubMed ID: 31907749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nomogram based on quantitative dynamic contrast-enhanced magnetic resonance imaging, apparent diffusion coefficient, and clinicopathological features for early prediction of pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy.
    He M; Su J; Ruan H; Song Y; Ma M; Xue F
    Quant Imaging Med Surg; 2023 Jul; 13(7):4089-4102. PubMed ID: 37456283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
    Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
    Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis.
    Jankowski C; Guiu S; Cortet M; Charon-Barra C; Desmoulins I; Lorgis V; Arnould L; Fumoleau P; Coudert B; Rouzier R; Coutant C; Reyal F
    Breast Cancer Res Treat; 2017 Jan; 161(1):73-81. PubMed ID: 27807808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laboratory indicators predict axillary nodal pathologic complete response after neoadjuvant therapy in breast cancer.
    Chen P; Zhao T; Bi Z; Zhang ZP; Xie L; Liu YB; Song XG; Song XR; Wang CJ; Wang YS
    Future Oncol; 2021 Jul; 17(19):2449-2460. PubMed ID: 33878939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dynamic change of neutrophil to lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients.
    Dan J; Tan J; Huang J; Zhang X; Guo Y; Huang Y; Yang J
    Breast Cancer; 2020 Sep; 27(5):982-988. PubMed ID: 32306184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction of Nomograms for Predicting Pathological Complete Response and Tumor Shrinkage Size in Breast Cancer.
    Yan S; Wang W; Zhu B; Pan X; Wu X; Tao W
    Cancer Manag Res; 2020; 12():8313-8323. PubMed ID: 32982426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer.
    Avci N; Deligonul A; Tolunay S; Cubukcu E; Fatih Olmez O; Ulas A; Hartavi M; Kurt E; Evrensel T
    J BUON; 2015; 20(1):45-9. PubMed ID: 25778295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.